Emerging pathogens – mycolab.ai

Candida vulturna, the Next Fungal Menace? A Narrative Review

mycolabadmin

Candida vulturna is a newly discovered yeast that causes serious blood infections, particularly in vulnerable patients like premature infants and those with cancer. Though still rare, cases are increasingly appearing in tropical regions with documented hospital outbreaks. While the infection has a better survival rate than related species, it resists several common antifungal drugs, making treatment challenging and requiring careful use of remaining effective medications.

First Report of Trametes hirsuta, Causal Agent White Rot in Avocado Trees Grown in the State of Michoacán, México

mycolabadmin

Researchers discovered that a wood-decay fungus called Trametes hirsuta is causing serious damage to avocado trees in Michoacán, México, the world’s largest avocado-producing region. The fungus infects tree trunks and branches, causing white rot that eventually kills the trees. About 60% of surveyed avocado trees showed signs of infection. Laboratory experiments confirmed that this fungus, previously known only as a decomposer of dead wood, can actively infect and destroy living avocado trees through wounds in the bark.

The impact of climate change on the epidemiology of fungal infections: implications for diagnosis, treatment, and public health strategies

mycolabadmin

Climate change is making it easier for dangerous fungi to grow and spread to new areas where people have never encountered them before. As temperatures rise and weather becomes more extreme, fungi are becoming resistant to our medicines, especially antifungal drugs used in both farming and hospitals. People living in poverty, displaced by natural disasters, and those without good healthcare access are most vulnerable to these infections. We need to act quickly by developing new treatments, improving diagnosis, reducing agricultural fungicide use, and strengthening healthcare systems in vulnerable communities.

Candida blankii: The Difficult Capture of a Fungus With Pathogenic Potential

mycolabadmin

Candida blankii is a rare fungal pathogen that is increasingly being found in hospital patients’ bloodstreams and respiratory tracts. The organism is difficult to identify using standard laboratory tests, which can delay diagnosis and treatment. This case report describes two adult patients with C. blankii infections and highlights the challenges in identifying this emerging pathogen and its resistance to common antifungal medications.

Spread of Antifungal-Resistant Trichophyton indotineae, United Kingdom, 2017–2024

mycolabadmin

A fungal infection called Trichophyton indotineae, which originated in Asia, is rapidly spreading throughout the United Kingdom and becoming resistant to common antifungal treatments. The infection typically starts in the groin area and can spread to other parts of the body, and many cases fail to respond to standard antifungal drugs like terbinafine. Researchers tracked 157 cases over seven years and found the fungus now accounts for over a third of all dermatophyte infections sent to the UK reference laboratory. Doctors and laboratory professionals are being urged to recognize this emerging threat and consider better diagnostic and treatment strategies.

Characteristics of Chrysosporium spp. Pathogens Causing Skin Mycoses in Horses

mycolabadmin

Researchers in Kazakhstan discovered two new fungal pathogens affecting horses’ skin for the first time. These fungi, called Chrysosporium kreiselii and Chrysosporium zonatum, cause skin lesions and dandruff in horses. One strain is resistant to most antifungal medications, making it particularly challenging to treat.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health threat, especially for people with weakened immune systems, causing millions of deaths annually. Currently available antifungal drugs are limited and increasingly face resistance, making them less effective over time. This special collection of research papers explores new approaches to treating fungal infections, including novel drugs, combination therapies, and alternative treatments to overcome resistance. Scientists and doctors hope these advances will help save more lives by providing better options for treating serious fungal diseases.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections affect over a billion people worldwide and are becoming harder to treat due to growing resistance to antifungal medications. The review discusses major challenges in detecting and treating these infections, including difficulty in diagnosis and limited awareness among healthcare providers. New antifungal drugs are being developed and approved to address these challenges, but a comprehensive approach involving better awareness, improved testing, and responsible medication use is needed.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

Research Topic: Emerging pathogens